|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-3-17
|
|
pubmed:abstractText |
It has been suggested that Id-1 has a critical role in the tumour progression and aggressiveness of several human cancers. However, the clinicopathological and biological significance of Id-1 overexpression remains unclear in human primary cancer. To investigate the association between Id-1 expression and cell proliferation or tumour angiogenesis, we examined the cell cycle kinetic indices (the proliferation and apoptotic indices, PI and AI) and intratumoral microvessel density (MVD) in 65 human pancreatic cancers. We also investigated the relationship between its expression and various clinicopathological factors to determine the clinical significance of Id-1 overexpression. Out of a total 65 cases, 32 (49.3%) showed overexpression of Id-1 vs normal tissues. Id-1 expression was found to be significantly associated with MVD (P=0.002). In further analysis of subgroups with higher and lower Id-1 expression, tumours with higher Id-1 expression (scores 4 and 5) showed significantly higher MVD than tumours with lower expression of Id-1 (scores 2 and 3) (111.18+/-57.14 vs 64.13+/-28.19, P<0.001). However, no significant association was found between Id-1 overexpression and patient survival rate. No significant association was also found between Id-1 expression and cell cycle kinetic indices (PI or AI) in pancreatic cancer. Moreover, the overexpression of Id-1 protein was not correlated with any significant clinicopathologic factors. These findings indicate that Id-1 overexpression is closely related with tumour angiogenesis and a higher density of intratumoral vessel, but that it is not associated with a poorer prognosis of survival or a higher cell proliferative potential in human pancreatic cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-10487839,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-10537105,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-10567549,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-10728695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-10732787,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-11058077,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-11085505,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-11263669,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-11479201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-11507043,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-11896613,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-11992094,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-12016143,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-12359201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-12576450,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-7547505,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-8139914,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-9109485,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-9315646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-9443985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-9528806,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-9640218,
http://linkedlifedata.com/resource/pubmed/commentcorrection/15026801-9671467
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
22
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1198-203
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15026801-Adenocarcinoma,
pubmed-meshheading:15026801-Adult,
pubmed-meshheading:15026801-Aged,
pubmed-meshheading:15026801-Cell Cycle,
pubmed-meshheading:15026801-Cell Division,
pubmed-meshheading:15026801-Disease Progression,
pubmed-meshheading:15026801-Female,
pubmed-meshheading:15026801-Gene Expression Profiling,
pubmed-meshheading:15026801-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15026801-Helix-Loop-Helix Motifs,
pubmed-meshheading:15026801-Humans,
pubmed-meshheading:15026801-Immunohistochemistry,
pubmed-meshheading:15026801-Inhibitor of Differentiation Protein 1,
pubmed-meshheading:15026801-Male,
pubmed-meshheading:15026801-Middle Aged,
pubmed-meshheading:15026801-Neovascularization, Pathologic,
pubmed-meshheading:15026801-Pancreatic Neoplasms,
pubmed-meshheading:15026801-Prognosis,
pubmed-meshheading:15026801-Repressor Proteins,
pubmed-meshheading:15026801-Survival Analysis,
pubmed-meshheading:15026801-Transcription Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Overexpression of Id-1 is significantly associated with tumour angiogenesis in human pancreas cancers.
|
|
pubmed:affiliation |
Departments of Internal Medicine and General Surgery, Samsung Medical Center, Sungkyunkwan University, School of Medicine, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
